Inhibitors targeting BCL-XL (AT-101, ABT-263) and MCL-1 (AZD5991, MIK665, AMG 176) have been developed for DLBCL and are undergoing clinical trials [27,28]. Here, MCL1 is linked to diffuse large B-cell lymphoma.